BTIG Reiterates Buy Rating on Aldeyra Therapeutics (ALDX)

November 18, 2024 10:22 AM EST Send to a Friend
BTIG analyst Thomas Shrader reiterated a Buy rating and $11.00 price target on Aldeyra Therapeutics (NASDAQ: ALDX)The analyst comments "The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login